繁體版 / 簡體版
 
R&D PORTFOLIO
/ SNP-810 (SAFETYNADOL)

SNP-810 (SAFETYNADOL)

Indication
Hepatotoxicity-free Acetaminophen (Analgesic and antipyretic)
Product Advantages
1. Hepatotoxicity-free
2. To address the important and urgent unmet medical needs
3. A patented formulation with great safety margin
Status
Phase I low-dose, high-dose completed (Pivotal trial applying for USFDA NDA)
Competitive Edge
1. Currently, no hepatotoxicity-free acetaminophen on the market
2. Great impact on the market share of pain controllers, especially to NSAIDS, Cox2 inhibitors and opioids
3. Reduction of lawsuit and compensation
Potential Market
Acetaminophen sales are 1.3 billion USD a year (US only)

Mechanism of Action of SNP-810 and NAC


陕西快乐十分中奖技巧 新疆18选7的开奖结果 民国扑克麻将有价值吗 6场半全场投注技巧 双色球周二走势图 冰球突破豪华版传奇 亿客隆 玩重庆幸运农场怎么玩 篮球即时比分90vs 时时彩走势图杀号技巧公式 十华人网络十平码专区十明日大富翁 A8百家乐娱乐城 广东快乐十分随机号码 电竞比分网 手机 安徽时时彩快3走势图一首页 dg视讯游戏平台下载 足彩胜负彩投注